The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells

International Journal of Environmental Research and Public Health

Volumn 7, Issue 5, 2010, Pages 2018-2032

  Stevens, Jacqueline J ^a   Graham, Barbara ^a   Walker, Alice M ^a   Tchounwou, Paul B ^a   Rogers, Christian ^a  

^a Jackson State University   (United States)

Author keywords

Arsenic trioxide; Comet assay; Genotoxicity; HT 29 cells

Indexed keywords

ARSENIC TRIOXIDE; MUTAGENIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE; THYMIDINE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA SYNTHESIS; DRUG MECHANISM; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; COLON TUMOR; DNA REPLICATION; DRUG EFFECTS; GENETICS; HT 29 CELL LINE; METABOLISM; PATHOLOGY;

ARSENICALS; COLONIC NEOPLASMS; COMET ASSAY; DNA DAMAGE; DNA REPLICATION; HT29 CELLS; HUMANS; MUTAGENS; OXIDES; THYMIDINE;

EID: 77954797986     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph7052018     Document Type: Article

References (52)

1. Jermal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer Statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Tapio, S.; Grosche, B. Arsenic in the aetiology of cancer. Mutat. Res. 2006, 612, 215-246.
3. Ghosh, P.; Banerjee, M.; Giri, A.K.; Ray, K. Toxicogenomics of arsenic: classical ideas and recent advances. Mutat. Res. 2008, 659, 293-301.
4. Tchounwou, P.B.; Patlolla, A.K.; Centeno, J.A. Carcinogenic and systemic health effects associated with arsenic exposure-a critical review. Toxicol Pathol. 2003, 31, 575-588.
5. IARC. Monographs on the Evaluation of Carcinogenic Risks of Chemcials to Humans. Supplement F. Overall Evaluation of Carcinogenicity; International Agency for Research on Cancer, World Health Organization: Lyon, France, 1987; pp. 29-55.
6. Tchounwou, P.B.; Centeno, J.A.; Patlolla, A.K. Arsenic toxicity, mutagenesis and carcinogenesis: a health risk assessment and management approach. Mol. Cell Biochem. 2004, 255, 47-55.
7. Tchounwou, P.B.; Wilson, B.; Ishaque, A. Important considerations in the development of public health advisories for arsenic and arsenic-containing compounds in drinking water. Rev. Environ. Health 1999, 19, 133-143.
8. Roy, P.; Saha, A. Metabolism and toxicity of arsenic: A human carcinogen. Curr. Sci. 2002, 82, 38-45.
9. Abernathy, C.; Liu, Y.; Longfellow, D.; Aposhian, V.; Beck, B.; Fowler, B.; Goyer, R.; Menzer, R.; Rossman, T.; Thompson, C.; Waalkes, M. Arsenic: health effects, mechanism of actions, and research issues. Environ. Health Perspect. 1999, 107, 1-8.
10. Kitchin, K.T. Recent advances in arsenic carcinogenesis: Modes of action, Animal Model Systems, and Methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 2001, 172, 249-261.
11. Kligerman, A.D.; Doerr, C.L.; Tennant, A.H.; Barrington-Brock, K.; Allen, J.W.; Winkfield, E.; Poorman-Allen, P.; Kundu, B.; Funasaka, K.; Roop, B.C.; Mass, M.J.; DeMarini, D.M. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ. Mol. Mutagen. 2003, 42, 192-205.
12. Galanis, A.; Karapetsas, A.; Sandaltzopoulos, R. Metal-induced carcinogenesis, oxidative stress and hypoxia signaling. Mutat. Res. 2009, 674, 31-35.
13. Hughes, M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 2002, 122, 1-16.
14. Miller, W.H.; Schipper, H.M.; Lee, J.S.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893-3903.
15. Frumkin, H.; Thun, M.J. Arsenic. CA J. Clin. 2001, 51, 254-262.
16. Guo, H. Cancer risks associated with arsenic in drinking water. Environ. Health Perspect. 2007, 115, A339-A340.
17. Yoshida, T.; Yamauchi, H.; Fan, Sun, G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol. 2004, 198, 243-252.
18. NRC (National Research Council). Arsenic in Drinking Water: Update; National Academy Press: Washington, DC, USA, 1999.
19. NRC (National Research Council). Arsenic in Drinking Water: Update; National Academy Press: Washington, DC, USA, 2001.
20. Klein, C.B.; Leszczynska, J.; Hickey, C.; Rossman, T.G. Further evidence against a direct genotoxic mode of action for arsenic-induced cancer. Toxicol. Appl. Pharmacol. 2007, 222, 289-297.
21. Patlolla, A.; Tchounwou, P.B. Cytogenetic evaluation of arsenic trioxide toxicity in Sprague- Dawley rats. Mutat. Res. 2005, 587, 126-133.
22. Hartman, A.; Speit, G. Comparative investigations of the Genotoxic effects of metals in the single gelassay and the sister-chromatid exchange tests. Environ. Mol. Mutagen. 1994, 23, 299-305.
23. Jha, A.N.; Noditi, M.; Nilsson, R.; Natarajan, A.T. Genotoxic effects of sodium arsenite on human cell. Mutat. Res. 1992, 284, 215-221.
24. Hei, T.; Filipic, M. Role of Oxidative damage in the genotoxicity of arsenic. Free Radic Bio Med. 2004, 37, 574-581.
25. Graham-Evans, B.; Tchounwou, P.B.; Cohly, H.H.P. Cytotoxicity and proliferation studies with arsenic in established human cell lines: Keratinocytes, melanocytes, dendritic cells, dermal fibroblasts, microvascular endothethial cells, monocytes and T-cells. Int. J. Mol. Sci. 2003, 4, 13-21.
26. Gradecla, D.; Paris, J.; Waspwocz, W. Selected mechanisms of genotoxic effects of inorganic arsenic compounds. Int. J. Occup. Med. Environ. Health 2001, 14, 317-328.
27. Hartwig, A.; Asmuss, M.; Ehleben, I.; Herzer, H.; Kostelac, D.; Pelzer, A.; Schwerdtle, T.; Burkle, A. Interference by Toxic Metal Ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ. Health Perspect. 2002, 110, 797-799.
28. Huang, C.; Ke, Q.; Costa, M.; Shi, X. Molecular mechanisms of arsenic carcinogenesis. Mol. Cell Biochem. 2004, 255, 57-66.
29. Dong, Z. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ. Health Perspect. 2002, 110, 757-759.
30. Lynn, S.; Gurr, J.R.; Lai, H.T.; Jan, K.Y. NADH oxidase activation is involved in arsenite induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 2000, 86, 514-519.
31. Nakamuro, K.; Sayato, Y. Comparative studies of chromosomal aberration induced by trivalent and pentavalent arsenic. Mutat. Res. 1981, 88, 73-80.
32. Li, J.H.; Rossman, T.G. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol. Toxicol. 1989, 2, 1-9.
33. Murgo, A.J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001, 6, 22-28.
34. Chen, G.Q.; Zhu, J.; Shi, X.G.; Ni, H.U.; Zhong, H.J.; Si, G.Y.; Jin, X.L.; Tang, W.; Li, X.S.; Xong, S.M.; Shen, Z.X.; Sun, G.L.; Ma, J.; Zhang, P.; Zhang, T.D.; Gazin, C.; Naoe, T.; Chen, S. T.; Wang, Z.Y.; Chen, Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: arsenic trioxide induces NB 4 cell apoptosis with down-regulation of bcl-2 expression and modulation of PML-RAR c/PML proteins. Blood 1996, 88, 1052-1061.
35. Hu, J.; Liu, Y.F.; Wu, C.F.; Xu, F.; Shen, Z.X.; Zhu, Y.M.; Li, J.M.; Tang, W.; Zhao, W.L.; Wu, W.; Sun, H.P.; Chen, Q.S.; Chen, B.; Zhou, G.B.; Zelent, A.; Waxman, S.; Wang, Z.Y.; Chen, S.J.; Chen, Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 2009, 106, 3342-3347.
36. Munshi, N. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001, 6, 17-21.
37. Monzen, H.; Griffin, R.J.; Williams, B.W.; Amano, M.; Ando, S.; Hasegawa, T. Study of Arsenic Trioxide-induced Vascular Shutdown and Enhancement with Radiation in solid tumor. Radiation Medicine 2004, 22, 205-211.
38. Maeda, H.; Hori, S.; Ohizumi, H.; Segawa, T.; Kakehi, Y.; Ogawa, O.; Kakizuka, A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthioninesulfoximine. Cell Death Differentiation 2004, 11, 737-746.
39. Tice, R.R.; Agurell, E.; Anderson, D.; Burlinson, B.; Hartmann, A.; Kobayashi, H.; Miyamae, Y.; Ryu, J.; Sasaki, Y.F. Single Cell Gel/Comet Assay: Guidelines for In vitro and In vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35, 206-221.
40. Huang, Y.; Zhang, J.; McHenry, K.T.; Kim, M.M.; Zeng, W.; Lopez-Pajares, V.; Dibble, C.C.; Mizgerd, J.P.; Yuan, Z.M. Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res. 2008, 68, 9131-9136.
41. Stevens, J.J.; Graham-Evans, B.; Walker, A.M.; Tchounwou, P.B. Cytotoxic effect of arsenic trioxide in adenocarcinoma colorectal cancer (HT-29) cells. Metal Ions in Biology and Medicine 2008, 10, 458-462.
42. Tchounwou, P.B.; Wilson, B.A.; Abdelghani, A.A.; Ishaque, A.B.; Patlolla, A.K. Differential cytotoxicity and gene expression in human liver carcinoma (HepG2) cells exposed to arsenic trioxide, and monosodium acid methanearsonate (MSMA). Int. J. Mol. Sci. 2002, 3, 1117-1132.
43. Yedjou, C.G.; Tchouwou, P.B. In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell electrophoresis (Comet) assays. Mole. Cell Biochem. 2007, 301, 123-130.
44. Walker, A.M.; Stevens, J.J.; Tchounwou, P.B. Arsenic trioxide mediated cytotoxicity and cell proliferation in breast and lung carcinoma cell lines. Metal Ions in Biology and Medicine 2006, 9, 287-292.
45. Ye, J.; Li, A.; Liu, Q.; Wang, X.; Zhou, J. Inhibition of mitogen-activated protein kinase, kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin. Exp. Pharmacol. Physiol. 2005, 32, 1042-1048.
46. Hanadeh, H.K.; Trouba, K.L.; Amin, R.P.; Afshari, C.A.; Germolec, D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 2002, 69, 306-316.
47. Germolec, D.R.; Yoshida, T.; Gaido, K.; Wilmer, J.L.; Simeonova, P.P.; Kayama, F.; Burleson, F.; Dong, W.; Lange, R.W.; Luster, M.I. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 1996, 141, 309-318.
48. Trouba, K.J.; Wauson, E.M.; Vorce, R.L. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 2000, 164, 161-170.
49. Lee, H.R.; Cheong, J.; Kim, S.J.; Lee, N.S.; Park, H.S.; Won, J.H. Sulindac enhances arsenic trioxide-mediated apotosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Oncol. Rep. 2008, 20, 41-47.
50. Kent, C.R.; Eady, J.J.; Ross, G.M.; Steel, G.G. The comet moment as a measure of DNA damage in the comet assay. Int. J. Radiat. Biol. 1995, 67, 655-660.
51. Dopp, E.; von Recklinghausen, U.; Hartmann, L.M.; Stueckradt, I.; Polllok, I.; Rabieh, S.; Hao, L.; Nussler, A.; Katier, C.; Hirner, A.V.; Rettenmeier, A.W. Subcellular distribution of inorganic and methylated arsenic compounds in human urothelial cells and human hepatocytes. Drug Metab. Disposition 2008, 5, 971-979.
52. Guillamet, E.; Creus, A.; Ponti, J.; Sabbioni, E.; Fortaner, S.; Marcos, R. In vitro DNA damage by arsenic compounds in a human lymphoblastoid cell line (TK6) assessed by the alkaline Comet assay. Mutagenesis 2004, 19, 129-135.